Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Merz

- PMLiVE

AbbVie creates new aesthetics division amid Allergan takeover

New separate business unit will operate own R&D functions

- PMLiVE

Brexit nears as Conservatives sweep to victory in election

British pharma association 'looks forward to working with the new Government'

- PMLiVE

AZ, Daiichi Sankyo strengthen case for HER2 candidate

Will rival Roche's HER2 franchise if approved

- PMLiVE

Seattle Genetics moves to dismiss ADC lawsuit with Daiichi Sankyo

US-based biotech is arguing the legal action is improper

- PMLiVE

UK is a leader in early clinical research but falls in later study stages, says ABPI

The UK faces challenges to stay competitive in clinical research globally

Daiichi Sankyo logo

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201

Dispute covers multiple drugs in Daiichi's antibody-drug conjugates pipeline

- PMLiVE

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs

Could add to AZ's portfolio of emerging cancer drugs

- PMLiVE

UK bans some drug exports to preserve NHS stocks

Insists the move is not related to Brexit

- PMLiVE

Labour Party takes aim at pharma, calls attention to Orkambi row

Proposal to introduce compulsory licensing faces industry criticism

Programmatic methodology and why you should be using it

What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director

Four Health

- PMLiVE

Prescription drug dependence ‘linked to deprivation’, says PHE

Public Health England publishes review on prescription rates

- PMLiVE

Government to set up ‘express freight service’ for medicinal products in event of no-deal Brexit

Additional preparation to ensure continuity of supplies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links